All News

infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
RheumNow Podcast square

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Jack Cush, MD

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
myositis, polymyositis, wikipedia

Skin Involvement with HMGCR Necrotizing Myositis

Jack Cush, MD

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.

Read Article
Jo1.gottrons.jpg

FDA Approves IVIG in Dermatomyositis

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).

Read Article
2020 Year Review

ICYMI: 2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
RheumNow Podcast square

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!

Read Article
pompe myopathy glycogen muscle

New, Improved Therapy for Pompe Disease

Jack Cush, MD

Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more favorable safety profile compared to the current standard of care (alglucosidase alfa).

Read Article
RheumNow Podcast square

RheumNow Podcast – Combination Biologics

Jack Cush, MD

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Links:

Dr. John Cush RheumNow ( View Tweet)

Differential Dx of immune-mediated necrotizing myopathies (IMNM) - HMGCR & Signal recognition particle Abs; checkpoint inhibitors, anti-Mi2 dermatomyositis, antisynthetase syndr. antimitochondrial Abs, GVHD, SARS-CoV-2 infection https://t.co/hhizx5gAet

Links:

Dr. John Cush RheumNow ( View Tweet)

Popular on RheumNow https://t.co/BZsl8a6ArW The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB

Links:

Dr. John Cush RheumNow ( View Tweet)
204 pts w/ dermatomyositis/polymyositis Rx w/ IV early pulse steroids(IVMP) or IVIG. IVMP & IVMP+IVIG was assoc w/ 56-58% incr odds of complete response. Pulse IVMP+IVIG incr risk of steroid D/C. Early IVMP/IVIG=no impact on mortality https://t.co/yRFJgos8Qq

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin

Links:

Dr. John Cush RheumNow ( View Tweet)
Septic arthritis MIMICs (all presenting as acute monoarthritis) - consider: cellulitis, bursitis, abscess, osteonecrosis, gout, pseudogout, Lyme, Osteomyelitis, reactive arthritis, Lyme disease,, Rheumatoid arthritis, & Transient synovitis (kids) https://t.co/uNirAcoBds

Links:

Dr. John Cush RheumNow ( View Tweet)

ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/4nNRRhzHVO

Links:

Dr. John Cush RheumNow ( View Tweet)
ProDERM OP0008: IVIG 2g/kg q4w for dermatomyositis vs PBO, open-label extension. TIS score responders 78% vs 43%. IVIG great option: Not immunosuppressive and works fast, watch for headache, pyrexia, nausea, risk of VTE. #EULAR2021 @RheumNow https://t.co/m4CEkg3EyC
Eric Dein ejdein1 ( View Tweet)
ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl
k dao KDAO2011 ( View Tweet)
2127 suspected myositis patients assayed for myositis Abs, ~1% tested positive for SAE Abs (small ubiquitin-like modifier (SUMO) activating enzyme) - present w/ rash first, followed by myositis, extramuscular involvement, sm risk for coincident cancer https://t.co/1f0GTcpdIo

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×